Modulation of calcineurin signaling during development

Area of Science:

• Neuroscience
• Developmental Biology
• Pharmacology

Background:

• Calcineurin signaling is suppressed in Down syndrome (trisomy 21) due to gene overexpression on chromosome 21, notably RCAN1 and DYRK1A.
• DYRK inhibitors are proposed therapeutics for Down syndrome, but their developmental safety and efficacy are largely unknown.

Purpose of the Study:

• To investigate the effects of modulating calcineurin signaling during development using zebrafish.
• To assess the potential benefits and risks of DYRK inhibitors as therapeutics for Down syndrome.

Main Methods:

• Zebrafish were exposed to calcineurin inhibitors (cyclosporine, tacrolimus) to mimic Down syndrome conditions.
• Developmental exposure to the DYRK inhibitor proINDY was evaluated for its effects on behavior and safety.

Main Results:

• Suppression of calcineurin signaling altered larval behaviors, with effects varying by exposure timing.
• ProINDY partially restored some behaviors but caused adverse effects, including reduced activity and visual responses.

Conclusions:

• The DYRK inhibitor proINDY demonstrates limited therapeutic benefits and significant risks during development.
• Zebrafish serve as an effective model for preclinical safety and efficacy testing of DYRK inhibitors for neural development in Down syndrome.